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Abstract 
 
Thyroid hormones act on almost all nucleated cells and are essential for growth, neuronal 
development, reproduction, and regulation of energy metabolism. Hypothyroidism and 
hyperthyroidism are common conditions that affect all populations worldwide, with 
potentially devastating health consequences.  Iodine nutrition is a key determinant of thyroid 
disease risk, however, other factors such as ageing, smoking status, genetic susceptibility, 
ethnicity, endocrine disruptors and the advent of novel biologic agents also influence thyroid 
disease epidemiology. In this report, we review the global incidence and prevalence of 
hyperthyroidism and hypothyroidism, highlighting geographical differences and the impact of 
environmental factors such as iodine supplementation. We highlight the pressing need for 
detailed epidemiological surveys of thyroid dysfunction and iodine status in developing 
countries. In the developed world, the prevalence of undiagnosed thyroid disease is likely 
falling, due to widespread thyroid function testing and relatively low thresholds for treatment 
initiation. However, continued vigilance against iodine deficiency remains essential in 
developed countries, particularly in Europe.  
 
 
 
 
  
	Introduction 
Thyroid hormones act on almost all nucleated cells and are essential for normal growth and 
energy metabolism1. Thyroid dysfunction is common, readily identifiable and easily treatable 
but if undiagnosed or untreated can have profound adverse consequences2,3. Despite an 
increase in thyroid disease awareness and the availability of sensitive laboratory assays for the 
measurement of thyroid hormones it is remarkable that instances of extreme thyroid 
dysfunction continue to occur4,5. Hypothyroidism and hyperthyroidism most commonly arise 
from pathology within the thyroid gland (primary thyroid disease), although rarely they may 
arise from disorders of the hypothalamus or pituitary (central) or from peripheral causes6. 
Conditions causing thyroid dysfunction are summarized in Figure 1. 
 
Because the clinical presentation of thyroid disease is highly variable and often non-specific 
the diagnosis of thyroid dysfunction is predominantly based on biochemical confirmation. 
The complex inverse association between the pituitary derived thyroid stimulating hormone 
(TSH) and the thyroid hormones, free thyroxine (FT4) and free tri-iodothyronine (FT3), 
renders TSH the more sensitive marker of thyroid status7. Accordingly, overt hypothyroidism 
is defined as TSH concentrations above the reference range and FT4 levels below the 
reference range while subclinical hypothyroidism is defined as TSH levels above the reference 
range, but FT4 levels within the population reference range8. Likewise, the reverse hormone 
pattern is applied in the definition of overt (low TSH, high FT4) and subclinical 
hyperthyroidism (low TSH, normal FT4). 
 
Iodine is an integral component of thyroid hormones but is unevenly distributed globally9. 
Over a billion people worldwide live in iodine deficient areas with populations at greatest risk 
residing in remote mountainous regions such as in South-East Asia, South America and 
Central Africa10. Population differences in iodine nutrition play a major role in the global 
prevalence of thyroid dysfunction. Nodular thyroid disorders are more prevalent in iodine 
deficiency while autoimmune thyroid disorders including Hashimoto’s thyroiditis and Graves’ 
disease occur more frequently in iodine-replete populations. However, a multitude of other 
risk factors including genetic and ethnic susceptibility, gender11, smoking12, alcohol 
consumption9,13-15, presence of other auto-immune conditions16, syndromic conditions17  and 
drug exposures18,19 also influence thyroid disease epidemiology20 (Table 1). Lastly, the 
detection of thyroid dysfunction is driven by clinical practice trends21 and in recent decades, 
progressive lowering of treatment thresholds together22 with increased thyroid function testing 
	with sensitive assays has led to a higher prevalence of so called borderline or mild cases22. 
This review summarises the current epidemiology of hyperthyroidism and hypothyroidism 
and highlights global differences and environmental factors that influence disease occurrence.    
 
Epidemiology of Hyperthyroidism 
Overview 
The prevalence of overt hyperthyroidism ranges from 0.2 to 1.3% in iodine sufficient parts of 
the world23,24 (Table 2). In the UK Whickham study the incidence of hyperthyroidism was 
estimated at between 100-200 cases per 100,000 a year with a prevalence of 2.7% in women 
and 0.23% in men, taking into account both established and possible cases25. These figures 
were considerably higher than earlier retrospective data from the USA which reported an 
incidence of 30 cases per 100,000/year for Graves’ disease in the period 1935-196726. A 20-
year follow up of the Whickham cohort showed an ongoing incidence of 80 cases/100,000 
women/year24,27. In the United States National Health and Nutrition Examination Survey 
(NHANES III) overt hyperthyroidism was detected in 0.5% of the population while 0.7% of 
the population had subclinical hyperthyroidism24  with an overall prevalence of 1.3%. Studies 
from several other countries including Sweden28,29 Denmark30, Norway31, and Japan32 have 
all reported comparable incidence and prevalence rates. A meta-analysis of European studies 
estimated a mean prevalence rate of 0.75% and an incidence rate of 51 per 100,000 per 
year23.   
 
Global variation in the epidemiology of hyperthyroidism (Figure 2) 
The prevalence and incidence of thyroid dysfunction is difficult to compare across countries 
due to differences in diagnostic thresholds, assay sensitivities, population selection, and fluxes 
in iodine nutrition and population dynamics (Table 2). Furthermore, the precise causes of 
hyperthyroidism are not always reliably defined. The prevalence of overt hyperthyroidism is 
roughly similar in Europe and the United States (0.7 vs. 0.5%)23,24. In Australia a slightly 
lower prevalence of 0.3% was reported for each of overt and subclinical hyperthyroidism33 
while a five-year incidence of hyperthyroidism was estimated at 0.5%34. In general the 
incidence of hyperthyroidism corresponds with population iodine nutrition with higher rates 
in iodine deficient countries, mostly due to an excess of nodular thyroid disease in the 
elderly35,36. For example in Pescopagano, an iodine deficient village of Southern Italy, the 
prevalence of hyperthyroidism was much higher at 2.9% than in iodine sufficient countries, 
mostly due to an excess of cases of toxic nodular goiters37. A cross sectional study in China 
	reported a higher prevalence of overt and subclinical hyperthyroidism in an iodine sufficient 
area compared to an iodine deficient area (1.2% vs 1.0%; P<0.001)38. These differences were 
however not seen either in China or in Japan when iodine sufficient areas were compared to 
areas with excessive iodine intake32,39.  
In Africa the epidemiology of thyroid dysfunction has proved more challenging to monitor 
due to a lack of comprehensive population based studies40. Existing studies are largely 
sourced from hospital based cohorts that exclude large segments of the rural population41 and 
are unlikely to be representative of the general population. A population study from several 
elderly care homes in Cape Town indicated a prevalence of 0.6% and 1.7% of 
hyperthyroidism and hypothyroidism respectively, with two-thirds of cases being  previously 
undiagnosed42. However, this study only included a population of Caucasian or mixed 
descent, and not black South Africans. In Johannesburg in 1981, the incidence of Graves’ 
disease was 5.5 per 100,000/year which was substantially lower than rates reported in the rest 
of the world43. However, a 60% rise in Graves’ disease incidence was observed over a 10 year 
period possibly due to improvements in dietary iodine intake amongst urban migrants43. 
Recent hospital based studies from Ghana show that contrary to earlier reports, Graves’ 
disease is not uncommon, comprising 54% of all cases of thyroid dysfunction44 although there 
may be ascertainment bias. While this may be due to improvements in iodine nutrition 
subsequent studies in the aftermath of iodisation in Ghana has shown marked increases in the 
incidence of both Graves’ disease and nodular disease suggesting a role for improved 
diagnosis45. 
 
Aetiology and clinical phenotype 
Graves' disease is the most common cause of hyperthyroidism in iodine replete populations. 
Other common causes include toxic multinodular goiter and autonomously functioning 
thyroid adenoma10 while less common causes are thyroiditis, pituitary TSH secreting 
adenoma, and drug induced hyperthyroidism. In iodine sufficient countries Graves’ disease 
accounts for 70-80% of patients with hyperthyroidism29 whereas in areas with iodine 
deficiency, Graves’ disease constitutes about half of all cases of hyperthyroidism with the 
other half attributable to nodular thyroid disease35. These differences were elegantly 
demonstrated in the classic epidemiological studies conducted by Laurberg et al in the 
ethnically identical Northern European populations of Iceland and Denmark. They showed a 
	high prevalence of Graves’ disease in the iodine sufficient Iceland compared to a  
predominance of toxic multinodular goiter in Denmark with its lower iodine intake35.  
 
The clinical phenotype in hyperthyroidism also shows geographical variation. Compared to 
patients with nodular disease Graves’ disease patients are younger, have higher thyroid 
hormone levels, and are more likely to present with overt than subclinical hyperthyroidism29. 
Cardiovascular complications appear to be more prevalent in areas where toxic multinodular 
goitres are common in part due to the older age of patients with nodular disease. Sub-
Saharan African populations suffer a disproportionate cardiovascular disease burden and it is 
uncertain whether this is due to genetic susceptibility or to socio-economic factors that 
promote late presentation and poor disease control46. Ethnicity does seem to influence the 
risk of developing certain disease complications. For examples Graves ophthalmopathy is six 
times more common in Caucasians than in Asians47. Furthermore, the rare but serious 
complication of hyperthyroidism, thyrotoxic periodic paralysis is significantly more common 
in Asian men. In China and Japan48 periodic paralysis has an incidence of 2% compared to 
0.2% in North America49. The genetic basis of this condition has been extensively studied 
and variations in certain HLA haplotypes such as DRw8, A2, Bw22, Aw19, and B17 have 
been identified in patients of Chinese or Japanese origin50 .  
 
Graves’ disease 
Graves’ disease is characterized by hyperthyroidism and diffuse goiter; ophthalmopathy, 
pretibial myxedema and thyroid achropachy may also be observed. The pathogenesis of this 
enigmatic condition remains incompletely understood but the central pathogenetic event is 
the unregulated stimulation of the TSH receptor by autoreactive TSH receptor antibodies 
(TRAbs). Graves’ disease has been described throughout the globe10 and predominantly 
affects women (female: male ratio 8:1), typically in their 3rd to 5th decades of life2. Recent 
observational studies suggest that the clinical phenotype of Graves’ disease, at least in 
Western countries, is becoming milder, presumably due to earlier diagnosis and treatment51. 
Graves ophthalmopathy occurs in 20-30% of patients while pretibial myxedema is now rarely 
observed52. A recent European survey showed a declining incidence of severe thyroid eye 
disease possibly due to reduction in smoking rates together with more effective management 
of early stage disease in multidisciplinary clinic set-ups53. 
	
 
	Toxic nodular disease 
Toxic nodular goitre is the most frequent cause of thyrotoxicosis in the elderly, especially in 
iodine deficient areas54. Solitary toxic nodules are more common in women than in men with 
a 1:5 M:F ratio reported in some studies29,55. In low iodine intake area the incidence of toxic 
multinodular goitre was 18.0 cases per 100,000/year compared to 1.5 cases per 100,000/year 
in a high iodine intake area (p <0.001)35. The incidence of solitary toxic nodules was similarly 
higher in low iodine intake (3.6 vs. 1.6 per 100,000/year; p <0.05)35. In a stable iodine 
sufficient area of Sweden, incidence rates for toxic multinodular goitre and solitary adenoma 
were 4.3 and 1.8 per 100,000/year respectively29. 
 
Thyroiditis 
Thyroiditis is characterized by a self-limiting course of thyrotoxicosis, followed by 
hypothyroidism, and then return to normal thyroid function56. It is slightly more common in 
females than males (ratio of 1.5:1)57 and permanent hypothyroidism occurs in 10-20% of 
cases. Acute painful thyroiditis often presents following a respiratory tract infection58 while 
painless thyroiditis may occur post-partum in up to 9% of otherwise normal women. Details 
of the epidemiology of painless thyroiditis are however limited. One registry study in 
Minnesota showed an estimated incidence of 4.9 cases per 100,000/year with permanent 
hypothyroidism in 15% of people59. On the other hand a Danish scintigraphy based study 
estimated the incidence of painless thyroiditis to be only 0.49 cases per 100,000/year60. Data 
from iodine-rich coastal areas of Japan suggested that as much as 10% of thyrotoxic patients 
had painless thyroiditis in contrast to 2.4% of thyrotoxic patients in New York61. Some 
authors have argued that this variation may be due to increases in iodine intake in previously 
iodine deficient regions61 although ascertainment bias remains possible.  A poll of 
endocrinologists indicated that silent thyroiditis was uncommon in Europe, Argentina, and 
coastal areas of the United States but was more prevalent around the Great lakes of the 
United States and Canada62. 
 
Drug induced hyperthyroidism 
The iodine-rich compound Amiodarone has been available since the 1960s and remains 
widely used as an anti-arrhythmic agent. Amiodarone induced thyrotoxicosis is more 
common in iodine deficient areas63 and appears to be more common in men63. The reported 
prevalence is highly variable ranging from 1-38%63-65 with more detailed reported rates of 
3% in North America66 and 5.8% in Japan67.However, these results need to be interpreted 
	with caution as the precise definition of AIT and the frequency of patient monitoring are key 
determinants of the observed prevalence. Other drugs that cause thyrotoxicosis include 
interferon-α, lithium, tyrosine kinase inhibitors, highly active antiretroviral therapies 
(HAART), immune checkpoint mediators and the humanised monoclonal antibodies used in 
the treatment of multiple sclerosis. Although these drugs may cause transient thyrotoxicosis 
through destructive thyroiditis the immune modifying agents such as interferon-α, HAART, 
and alemtuzumab may in addition induce Graves’ diseases through less well-defined immune 
reactivation mechanisms.  
 
Subclinical hyperthyroidism 
Precise estimates of the prevalence of subclinical hyperthyroidism are difficult because 
epidemiological studies use different diagnostic thresholds. Studies report figures ranging 
from 1 to 5% 68 although some of these include patients on levothyroxine10. Data from the 
NHANES III study suggest a bimodal peak at age 20-39 years and at 80 years and above24. 
The NHANES study also showed that women were more likely to have a TSH level less than 
0.4 mU/l and that ethnicity influenced the risk of having subclinical hyperthyroidism with 
blacks having a prevalence of 0.4%, Mexican Americans 0.3%, and whites 0.1%24. In Asia, 
prevalence ranges between 0.43% to 3.9% of the general population. Globally, the greatest 
risk factor for subclinical hyperthyroidism aside from levothyroxine use is iodine deficiency 
with the prevalence of subclinical hyperthyroidism rising to 6-10% in iodine deficient areas, 
largely due to toxic nodular goitres10. In the UK a TSH level <0.1 mU/L was observed in 5.8 
% of levothyroxine-treated patients while 10.2% had TSH 0.1-0.5 mU/l with women more 
likely to be over-replaced22. There is limited data on the risk of progression from subclinical 
to overt hyperthyroidism. In a Scottish database comprising 2,024 cases of subclinical 
hyperthyroidism the vast majority of untreated patients did not progress to overt 
hyperthyroidism and a third returned to normal thyroid status seven years later69. Other 
studies showed that patients with more severe grades of subclinical hyperthyroidism 
progressed more frequently to overt disease70,71.   
 
Iodine induced hyperthyroidism 
Iodine-induced hyperthyroidism, the Jod-Basedow phenomenon, is commoner in older 
persons with long standing nodular goitre and in regions of chronic iodine deficiency72 
undergoing iodine supplementation. Iodisation programs temporarily increase the risk of 
	iodine induced hyperthyroidism; the risks are principally to the elderly who may have co-
existing cardiac disease and also to those with limited access to healthcare72. Radiographic 
contrast agents, also cause iodine induced hyperthyroidism. Individuals with pre-existing 
multinodular goitre or those from iodine deficient areas are at greatest risk73,74. 
 
Pregnancy 
Thyrotoxicosis in pregnancy has  an estimated incidence of 0.2% for overt thyrotoxicosis and 
2.5% for subclinical thyrotoxicosis. More recent data from the USA estimates the incidence 
to be 5.9 per 1000 pregnant women per year75. The greatest risk of hyperthyroidism appears 
to be in the first trimester76.  Graves’ disease is the most common cause of thyrotoxicosis in 
pregnancy2 although other causes may also occur during gestation. The occurrence of 
hyperthyroidism in pregnancy may however be over-estimated by inclusion of cases of 
gestational thyrotoxicosis, a benign and transient disorder of pregnancy that typically occurs 
in the first trimester2. The management of thyrotoxicosis in pregnancy is complex and has to 
address the risk of maternal hyperthyroidism with that of fetal harm from transplacental 
transfer of maternal antibodies and thionamide drugs77,78.  
	
Treatment of Hyperthyroidism 
There is surprisingly substantial global variation in the treatment of hyperthyroidism. The 
choice of anti-thyroid drugs, radio-iodine or surgery may have a modest impact on the 
epidemiology of hypothyroidism given that radio-iodine and surgery ultimately result in 
permanent hypothyroidism. Unlike in Europe, USA endocrinologists have traditionally 
preferred radio-iodine over anti-thyroid drugs. Two-thirds of American Thyroid Association 
(ATA) respondents favoured the use of radio-iodine as the primary treatment modality for 
Graves’ disease whereas only 20% of members of European and UK thyroid societies would 
use radioiodine as primary therapy79. In Korea 10% of practitioners recommended 
thyroidectomy as first line treatment for Graves’ disease in contrast to other regions where 
thyroidectomy is hardly used79 For pragmatic reasons thyrotoxicosis in African countries is 
treated with anti-thyroid drugs or surgery due to limited availability of radioisotopes80.  
 
Epidemiology of Hypothyroidism 
 
Overview 
Iodine deficiency and auto-immune disease (Hashimoto’s) account for the vast majority  of 
cases of primary hypothyroidism3. A third of the world’s population live in iodine deficient 
	areas and the devastating consequences of severe iodine deficiency on fetal and child 
neurological development are well recognised9. Furthermore, there is increasing concern of 
the possible effects of less severe grades of iodine deficiency during pregnancy on offspring 
cognitive development81. Changes in diet and agricultural practices have led to the re-
emergence of iodine deficiency in countries previously believed to be iodine sufficient 
including developed countries82. In Europe, 44% of school-age children still have insufficient 
iodine intake and countries such as the UK, Italy, and Spain now appear to be moderately 
iodine deficient83-90.  
 
In iodine sufficient countries, the prevalence of hypothyroidism ranges from 1-2%10,91 rising 
to 7% in individuals aged between 85-89 years92. In the absence of age-specific reference 
ranges for TSH an ageing population is likely to result in a higher prevalence of 
hypothyroidism. Hypothyroidism is approximately 10 times more common in women than 
men10. Data from Norway showed that the prevalence of untreated overt hypothyroidism was 
low at 0.1%, reflecting a fall of 84% from the 1990s. In the UK  the rate of new prescriptions 
of levothyroxine for primary hypothyroidism increased 1.74 fold between 2001-200922 
indicating widespread testing.  
 
Global variation in the epidemiology of hypothyroidism (Figure 3) 
The prevalence of overt hypothyroidism in the general population varies between 0.2% and 
5.3% in Europe93,94  and 0.3% and 3.7% in the USA95. depending on the definition used and 
population studied (Table 3). Longitudinal studies from large UK cohorts report an 
incidence rate of spontaneous hypothyroidism of 3.5 – 5.0 per 1000 and 0.6 – 1.0 per 1000 in 
women and men, respectively27,96. A survey conducted in Spain reported a prevalence of 
treated hypothyroidism, untreated subclinical hypothyroidism, and untreated clinical 
hypothyroidism of 4.2% 4.6 and 0.3%, respectively97. In Australia, the five-year incidence of 
hypothyroidism in individuals aged above 55 years  was 0.5% and 4.2% respectively34 while 
the prevalence of overt and subclinical hypothyroidism is estimated at 0.5% and 5.0% 
respectively33.The longest follow-up study is from the UK Whickham cohort25,27 where the 
mean annual incidence of spontaneous hypothyroidism during a 20 year follow-up period was 
35 cases per 10,000 surviving women and 6 per 10,000 surviving men27. Higher TSH levels 
and antibody positive were associated with increased risk of developing hypothyroidism with 
a positive interactive effect27.  
	In the NHANES study, the overall prevalence of hypothyroidism was 4.6%24. The prevalence 
was similar in Caucasians and Hispanic but was markedly lower in individuals of Afro-
Caribbean descent (1.7%). A study from Brazil demonstrated similar differences with the 
highest prevalence of hypothyroidism seen in white (1.6%) compared to people of black 
(0.59%) or mixed (1.27%) ancestry98. A separate study examined thyroid dysfunction in 
Brazilians of Japanese descent, with 0.8% found to have hypothyroidism and 8.9% subclinical 
hypothyroidism99. Intriguingly overall thyroid dysfunction rates were lower in a study based 
in Japan100 despite the older age range of the study population suggesting regional 
environmental differences.  
Data from the Arab world are limited. One systematic review101 evaluated 21 studies that 
addressed thyroid disease prevalence across ten Middle Eastern countries. However, there 
was wide heterogeneity in the populations studied and most of the available studies were 
convenience samples sourced from cohorts with high risk of thyroid dysfunction such as 
diabetes, thyroid cancer, or surgical and histopathological series. In Tehran, an iodine 
sufficient area of Iran, the annual incidence rates of subclinical and overt hypothyroidism 
were 7.62 and 2.0 per 1000 persons, respectively102 and in the same population thyroid 
antibodies were deteceted in 16% of women and 8% of men103  figures that are comparable 
to data from European populations104 
The overall disease burden of hypothyroidism in Sub-Saharan Africa based on largely 
hospital clinic data, has been generally felt to be minimal, even rare, and substantially lower 
than the prevalence found in African-Americans.  In a small hospital study in Lagos, Nigeria, 
the majority of patients seen in a thyroid clinic had hyperthyroidism105. In this study 
Hashimoto’s thyroiditis was diagnosed in only 6% of patients and positive thyroid peroxidase 
antibodies were detected in 4% of the healthy population105. However, the significant referal 
bias and exclusion of large numbers of the general population should question the 
generalizability of these figures. More recently, thyroid dysfunction has been highlighted in 
African as well as Asian patients with HIV on multi-drug resistant treatment regimens for 
tuberculosis with agents like ethionamide that inhibit thyroid hormone synthesis106. 
In China it is striking that in the last decade, the prevalence of subclinical hypothyroidism  
has increased (16.7% vs 3.22%), along with the proportion of the thyroid peroxidase antibody 
positive population107, reflecting the transition to iodine sufficiency107,108. Similar to China, a 
recent large cross-sectional multi-city study in India reported remarkably high rates of 
	hypothyroidism (10%) although this included self-reported cases109. Furthermore, regional 
variations were seen with higher rates in inland compared to coastal regions109.  There is now 
a growing appreciation in India that hypothyroidism represents a substantial health problem, 
despite  extensive universal salt iodisation110. The prevalence appears to be substantially 
higher than in Europe and the USA and whilst genetic and iodine factors are likely to pay a 
substantial role other factors including high levels of endocrine disruptors have been 
postulated to have an impact110.  
 
Hypothyroidism in pregnancy 
In iodine sufficient areas the prevalence of hypothyroidism in pregnancy is around 2%. 
Optimal control of thyroid status is essential for both obstetric and offspring outcomes 
although precise treatment thresholds are at present unclear111. Correction of both overt 
hypothyroidism and hyperthyroidism dramatically reduces the risk of fetal loss and preterm 
birth112,113. Subclinical hypothyroidism before 20 weeks of pregnancy is associated with an 
increased risk of miscarriage114 and isolated hypothyroxinemia (low FT4 normal TSH) is 
associated with adverse pregnancy outcomes including prematurity115. Randomised 
controlled trials in women with gestational subclinical hypothyroidism and isolated 
hypothyroxinemia however have failed to show benefits of levothyroxine therapy on offspring 
IQ116,117 or obstetric outcomes117. In these trials however levothyroxine was initiated from the 
end of the first trimester of pregnancy after the early critical phase of fetal brain development. 
Universal thyroid screening in pregnancy is therefore contentious although it has been shown 
to be cost-effective in analytical economic models118.  
 
Congenital Hypothyroidism (CH) 
Congenital hypothyroidism is one of the most common treatable cause of mental 
retardation119. Until recently congenital hypothyroidism was estimated to affect 
approximately 1 newborn in 3500–4000 births120 but over the last decade several screening 
programs have reported an increase in prevalence.  Analysis of data from the USA identified 
a near doubling of the incidence of CH in a 15 year period from 1987 at 1:3985 to 1:2273 in 
2002121. A similar change has also been observed in New Zealand122. Some of this increase is 
due to changes in the ethnicity of the populations studied although lowering of the TSH 
cutoff has contributed. Despite the clear advantages of birth screening programs it is 
estimated that only approximately 29.3% of the world's birth population is screened for 
CH123.  
	 
Drug induced hypothyroidism 
Several drugs are known to cause hypothyroidism until recently the most notable of which 
were lithium and amiodarone, and tyrosine kinase inhibitors. Lithium therapy causes overt 
hypothyroidism in between 5-15% of lithium-treated patients124 and in one study of 
laboratory data the use of lithium increased the risk of hypothyroidism by more than two-fold 
(OR = 2.31 95%CI 2.05, 2.60 p<0.000119). Amiodarone induced hypothyroidism is more 
common than amiodarone induced thyrotoxicosis in iodine sufficient areas125.  
 
Immune checkpoint inhibitors have emerged as key treatments in managing advanced 
cancers have the ability to reactivate the immune system against cancer cells, but can also 
induce autoimmune side effects which have a preponderance for the thyroid axis126. These 
agents can be given singly or in combination. Whilst these may not substantially increase the 
incidence of thyroid disease, the complexity of these patients may result in a substantial 
addition to specialist thyroid clinics.  
 
The key agents are anti-cytotoxic T- lymphocyte antigen 4 (CTLA-4 e.g. Ipilimumab) anti-
programmed cell death protein -1 (PD-1 e.g. Nivolumab and pembrolizumab) and anti-PD-1 
ligand molecules (PD-L1 and PD-L2). They have been approved for a variety of cancers 
including melanoma, non small cell lung cancer, renal cell carcinoma, Hodgkin’s lymphoma 
and head and neck cancers126. 
 
These immune checkpoint inhibitors can result in primary or secondary hypothyroidism and 
primary hyperthyroidism. Secondary hypothyroidism is more common with anti CTLA-4 
antibodies, where as primary hypothyroidism is seen more commonly with anti-PD-1  and 
anti-PD-L1 monoclonal antibodies126 . A recent meta-analysis127 of 38 randomized controlled 
trials comprising 7,551 patients used Ipilumumab (CTLA-4) as a baseline and identified that 
those who received combination therapy had the highest odds of  hypothyroidism OR=3.81 
(95%CI 2.10, 6.91), hyperthyroidism OR=4.27 (95%CI 2.05, 8.90) and hypophysitis 
OR=2.2 (95%CI 1.39, 3.60) . Those on PD-1 inhibitors also had a higher risk of developing 
hypothyroidism OR=1.89 (95%CI 1.17, 3.05)  than those on Ipilumumab.  
 
Alemtuzumab a novel treatment for multiple sclerosis has also been associated with a high 
prevalence of hypothyroidism128 . Tyrosine kinase inhibitors can result in an increased risk of 
	hypothyroidism with 27% of treated patients requiring levothyroxine129 during their 
treatment.  
 
Iodine induced hypothyroidism  
 
The underlying mechanism of iodine-induced hypothyroidism is not well understood, but is 
attributed to a failure of thyroid adaptive mechanisms to an acute iodide load (Wolff–
Chaikoff effect). Common sources of excess iodine include supplementation, diet, iodinated 
contrast agents, and medication. Discussion of the impacts of iodine fortification on the 
epidemiology of hypothyroidism and hyperthyroidism is shown below. 
 
Effect of iodine fortification on the prevalence and incidence of hypothyroidism 
and hyperthyroidism 
 
Over the last 25 years many countries across the globe have introduced universal salt 
iodisation programs which have seen a dramatic decline in the number of iodine deficient 
countries. As at 2016, 110 countries have now been classed as having optimal iodine intake 
while insufficient iodine intake persists in only 19 countries130. Iodine fortification of all food-
grade salt is now mandated in close to 120 countries131, although voluntary fortification 
programs do not allow for enforcement. Moreover, these initiatives require regular 
monitoring to ensure that fortification programmes meet changing demands, given the 
adverse outcomes of over or undersupply of iodine. In Europe, few countries have regular 
monitoring, but those engaged in regular studies are using heterogeneous methods and 
outcomes, which prohibit an appropriate comparison within meta-analyses.  
 
Table 4 summarizes some of the studies with longitudinal data that have surveyed the 
occurrence of thyroid dysfunction in relation to national iodisation programmes. These 
studies show variable trends that depend on pre-existing population iodine status, magnitude 
of iodisation and survey methodology. There is well documented evidence of an increase in 
the frequency of thyroid autoimmunity following iodisation programmes20,40,108,132. The 
mechanism of this phenomenon is complex but may be due to iodisation of thyroglobulin,133 
which enhances  immunogenicity through altered epitope expression134. From fortification 
programs in Denmark, it is apparent that even a cautious iodisation programme is associated 
with an increase in TPO antibodies from 14.3% and 23.8%135. As a result, the incidence of 
overt hypothyroidism increased almost 20% from 38.3/100.000 per year at baseline to 
	47.2/100.000 per year, an increase which was most marked in young and middle-aged 
individuals in an area of moderate iodine deficiency136.  
A study in Poland showed that hypothyroidism occurred more frequently after a mandatory 
iodine prophylaxis (2.1% vs. 1.4% in females and 0.3% vs. 0% in males)137. In an elderly 
Icelandic population with relatively high iodine intake, the prevalence of high serum TSH 
concentrations (> 4mU/l) was 18% whereas in subjects residing in Jutland, Denmark, with 
low iodine intake, high serum TSH levels were prevalent in 3.8% of the subjects showing that 
ingestion of smaller quantities of iodine could impact thyroid function in a population at 
large138. Similar to these findings, the prevalence of non-autoimmune hypothyroidism was 
12.1% in coastal areas of the Hokkaido Islands, Japan compared to 2.3% in non-coastal areas 
due to the high iodine intake from seaweed (kelp) consumption139. In a five year follow up 
study in China, the prevalence of  subclinical hypothyroidism and thyroid autoimmunity was 
highest in areas with excessive iodine nutrition status108. However data from Tasmania140, 
Bangladesh141 Sri-Lanka and Italy142 did not show an increase in hypothyroidism following 
iodine fortification although a minimal rise in TSH was observed in Italy142.  
One offshoot of iodisation is the risk of thyrotoxicosis secondary to excessive iodisation. A 
growing number of countries, 10 as at 2016, are now classed as having excessive iodine intake 
status. In the past, cases of iodine-induced thyrotoxicosis were observed following salt 
iodisation programmes or increases in dietary iodine intake143-146. Most notable of these 
occurred in the Tasmanian state of Australia145, in Harare, Zimbabwe144, and Kivu in 
Northern Zaire143. In these areas increases in cases of toxic nodular goitres were observed in 
the aftermath of iodisation with fatalities resulting from cardiovascular complications in some 
areas143. Susceptible population groups are typically elderly with longstanding nodular 
goitres. However, iodine induced thyrotoxicosis is transient and limited to instances of 
precipitous increases in iodine intake in areas of longstanding iodine deficiency or in urban 
migrants from iodine deficient areas40. A chronic state of excessive iodine nutrition has raised 
concerns in some sub-Saharan African countries9 and excess iodine nutrition has been 
reported amongst refugees and displaced populations within the region who rely on iodised 
salt sourced from food aid from regional governments and international aid agencies147,148.   
While these important observations call for continued vigilance of iodine supplementation 
programmes they should not deter from the goals of eradication iodine deficiency. 
 
 
	Conclusion 
This review has summarised the current epidemiology of hypothyroidism and 
hyperthyroidism and examined factors that affect disease prevalence. In iodine-sufficient 
areas, the majority of thyroid dysfunction is due to thyroid auto-immunity and data from 
Europe and other parts of the world has revealed the influence of variation in iodine status 
and the impact of iodine supplementation on the epidemiology of thyroid dysfunction9,23,82. 
Other factors that may impact on the epidemiology of thyroid disease is the increasingly 
widespread use of thyroid function testing93 lowering of thresholds for treatment, and 
introduction of novel therapeutic agents with effects on thyroid function. Also, this work has 
demonstrated striking geographical and ethnic differences in thyroid disease epidemiology. In 
Africian-American populations the frequency of hypothyroidism appears to be lower than in 
Caucasians24.  Careful re-analysis of NHANES indicates that non-Hispanic blacks had 54% 
lower risk of hypothyroidism than non-Hispanic whites, but had over a threefold higher risk 
of hyperthyroidism149. Data from Brazil shows a similar pattern with blacks having the lowest 
prevalence of hypothyroidism and those of dual heritage and whites having a higher 
prevalence (Table 3)98. In India striking regional variations in the prevalence of 
hypothyroidism has been reported raising the need for standardization of assay methods and 
regional and population specific reference ranges.  
 
A greater understanding of the genetic variants responsible for variation in TSH and thyroid 
hormone levels is emerging, but only a small proportion (<10%) of the genetic architecture 
has been explained to date150,151. Variants have been identified which increase the risk of 
Graves’ disease150,152 and also TPO antibody positivity150. Greater understanding of the 
genetic architecture is required particularly in non-Caucasian populations. Analysis of 
differences in risk variants identified in different populations would provide enhanced insight 
into the variations in thyroid disease globally and may also explain borderline TSH 
abnormalities. Currently, many individuals with modest TSH abnormalities are started on 
treatment 22 but such individuals would have spontaneously reverted to normal without 
intervention153. A recent trial of thyroid hormone therapy for older adults with subclinical 
hypothyroidism, the TRUST trial154, identified that up to 60% of potentially eligible elderly 
individuals with an elevated TSH had returned to euthyroidism when reassessed for the trial. 
The clinical significance of subclinical thyroid dysfunction or of variations in thyroid 
hormones within the laboratory reference range remain contentious155-158 and beyond the 
	scope of this review. However, genetic risk factor profiles may in future augment other risk 
factors in stratifying individuals with borderline TSH abnormalities151.   
  
There is still considerable controversy as to whether healthy adults in iodine sufficient areas 
will benefit from screening for thyroid disease. Targeted screening for thyroid dysfunction in 
pregnancy is commonplace and universal thyroid screening in pregnancy continues to 
generate impassioned  debate111  The prevalence of unsuspected thyroid disease is low in 
developed countries but a substantial proportion of individuals will have evidence of minor 
thyroid dysfunction93. However, at present no appropriately powered prospective, 
randomized, controlled, double-blinded interventional trial of either levothyroxine therapy 
for subclinical hypothyroidism or anti-thyroid therapy for subclinical hyperthyroidism exists 
in the healthy general younger adult population although data are emerging for older 
individuals158. 
 
It is striking that up to 50% of cases of subclinical hyperthyroidism have arisen from 
levothyroxine treatment especially as the threshold for treatment has fallen22. Whilst studies 
are urgently needed in the developed world on the incidence and prevalence of thyroid 
disease, studies are also needed on the consequences of current prescribing practice in the 
developed world with a greater clarification of treatment thresholds in pregnancy as well as 
the general population. Ongoing data capture of the prevalence and incidence of thyroid 
disease is still required in the developing world especially in areas where there are fluxes in 
population iodine nutrition. In the developed world, endeavours such as EUthyroid, a 
collaborative venture, promoting monitoring of iodine status and its consequences on thyroid 
disease epidemiology will be crucial. Such initiatives will need to be supported by appropriate 
randomised controlled trials in subclinical thyroid disease and in optimal management of 
hypothyroidism. 
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	Table 1 Risk factors for developing Hypothyroidism and Hyperthyroidism 
 
Risk factor Hypothyroidism Hyperthyroidism Comment 
Female Sex23 + + Sex hormones and the skewed inactivation of the X 
chromosome, are suspected to be triggers 
Iodine deficiency +  + Severe iodine deficiency may cause hypothyroidism 
Iodine excess + + Excess iodine status may trigger hyperthyroidism typically 
in elderly individuals with longstanding thyroid nodules 
Transition from 
iodine deficiency 
to sufficency 
+  Transition from iodine deficiency to sufficiency was 
associated with an increase in TPO antibodies from 14.3% 
and 23.8% in one study 135. As a result, the incidence of 
overt hypothyroidism increased almost 20% from 
38.3/100.000 per year at baseline to 47.2/100.000 per 
year 136. 
Other 
autoimmune 
conditions 
+ + One study reported that another auto-immune disease was 
present in almost 10% of patients with Graves’ disease and 
in 15% of patients with Hashimoto’s thyroidits with 
rheumatoid arthritis being the most common16.  
Genetic risk 
factors 
  Both Graves’ disease and Hashimoto’s thyroiditis have 
genetic predispositions. Genome wide association data 
have identified regions associated with TPO antibody 
positivity159 and thyroid disease159. 160. Whole genome 
sequence may reveal novel insights151. 
Smoking — + Current smoking increases the odds of Graves’ 
hyperthyroidism  almost 2 fold and increases the risk of 
Graves’ opthalmopathy almost 8 fold 161. Smokers also 
have a slower response  during antithyroid drug 
treatment162.  Smoking may protect against 
hypothyroidism as smokers have a 30-45% reduction in 
the odds of being TPO antibody positive 163,164. Current 
smokers had a 50% lower prevalence of subclinical 
hypothyroidism and a 40% lower prevalence of overt 
hypothyroidism with smokers 165.  
Alcohol —  Moderate alcohol intake may be associated with a reduced 
risk of hypothyroidism166 
Selenium 
deficiency 
+ + One study reported that patients with newly diagnosed 
Graves’ disease and hypothyroidism had lower selenium 
levels than the normal population, particularly in patients 
with Graves’ disease 15 
Drugs + + Examples include Amiodarone18,Lithium19, interferon 
gamma 
Infections   Infectious agents have been associated with both auto-
immune diseases and Graves’ disease167. The most well 
studied is Yersinia enterocolitica although retroviruses 
have been identified a13,167. 
Syndromic 
Conditions 
+  In Down’s syndrome almost 25% of patients in a large 
registry had thyroid disease, the commonest being primary 
hypothyroidism17. The prevalence of hypothyroidism in 
Turner’s syndrome is approximately 13%160 but the 
incidence increases substantially by the third decade. 
	
 
Table 2: Incidence and prevalence of hyperthyroidism in iodine sufficient and iodine deficient countries 
Author, country, publication 
year 
Study date Sample no Age, 
years 
Female, 
% 
Iodine 
intake/UIC 
Incidence per 105/year Prevalence, % 
M F Total M F Total 
IODINE SUFFICIENT  
Tunbridge, UK, 1977 25  1972-1974 2,779 >18 54 811 nmol/24h    0.2 1.9 1.1 
Mogensen, Denmark, 1980168 1972-1974 439,756 >0 50  8.7 46.5 27.6    
Berglund, Sweden, 1990169 1970-1974 258,000 >0 52  10.1 40.6 25.8    
Konno, Japan, 199332 1990-1991 4,110 Adult 29     0.3 0.5 0.3 
Galofre, Spain, 1994170 1990-1992 103,098 15–85 57  6.5 89.1 52.4    
Berglund, Sweden, 199628 1988-1990 231,774 >0 53  10.9 72.0 43    
Vanderpump, UK, 199527 1975-1994 1,877 38-93 56 102 µg/g cr 0 80 53 0.2 3.9 2.5 
Bjoro, Norway, 200031 1995-1997	 94,009 >20 50     0.1 0.3 0.2 
Canaris, USA, 200095 1995 24,337 >18 56       0.1 
Hollowell, USA, 200224 1988-1994	 13,344 >12  145 µg/l      0.2 
Volzke, Germany, 2003171 1997-2001	 3,941 20-79 48 12 µg/dL      0.4 
Flynn, UK, 200496 1993-1997	 369,885  >0   14 77 46   0.6 
O’ Leary 2006172 1981 2,115 16-89 50 
 
2,115 16-89 50     0.1 0.2 0.1 
Leese, UK, 2007173 1994-2001 388,750 >0 52  14 87  0.2 1.3 0.8 
Lucas, Spain, 2010174 2002 1,124 18-74 56 150 µg/l    0.2 0.2 0.2 
Asvold, Norway, 201293 1995-2008 15,106 >20 67  49.6 97.3 81.6    
Delshad, Iran, 2012 175 1999-2005 1,999 >20 61  21 140     
Unnikrishnan, India, 2013†109  2011 5376 18-100 53.7     0.62 0.72 0.67 
Sriphrapradang, Thailand, 2014176 2009 2545 ≥14 46       0.94 
Nystrom, Sweden, 201329 2003-2005 631, 239 >0  125 µg/l   27.6    
Valdes, Spain, 201797 2009-2010 4,554 18-93 58 117 µg/l      0.4 
IODINE DEFICIENT 
Kalk, South Africa, 198143 1974-1984 1,246,294 >15 48  0.7 8.8 5.5    
Aghini-Lombardi, Italy, 199937 1995 992 >15 58 55µg/l    2.9 3.0 2.9 
Knudsen, 1999, Denmark104 1993-1994 2,613 41-71 49 70µg/l    0 1.2 0.6 
	 
  
Knudsen, 2000, Denmark30 1997-1998 2,293 18-65 79 45µg/l      0.4 
Knudsen, 2000, Denmark30 1997-1998 2,067 18-65 79 61µg/l      0.8 
Hoogendoorn, 2006, Netherlands177 2002-2003 5,167 >18 54     0.2 0.6 0.4 
Laurberg, 2006, Denmark36 1997-1998 310,124 18-65 50 68µg/l 36 149.1 92.9    
Laurberg, 2006, Denmark36 1997-1998 225,707 18-65 53 53µg/l 26.8 101.7 65.4    
Data is for cases of overt hyperthyroidism except where otherwise stated. Iodine status is based on reported status by authors; spaces are left blank where there is no data on 
incidence or prevalence or where the data is unclear from the report. †same study population, studied at 5 and 11 year intervals post iodizaton. 
†Study from 8 cities with a wide mix of iodine status ranging from sufficient to deficient. Studies in specific population groups such as children, pregnant women, specificied co-
morbid states, and unstable iodine nutrition are excluded 
 
	
 
	
Table 3: Incidence and prevalence of hypothyroidism in iodine sufficient and iodine deficient countries 
Author, country, publication 
year 
Study 
date 
Sample 
no 
Age, years Female, 
% 
Iodine 
intake/UIC 
Incidence per 105/year Prevalence, % 
M F Total M F Total 
IODINE SUFFICIENT  
Tunbridge, UK, 1977 25 1972-1974 2,779 >18 54 811 nmol/24h    0.1 1.4 1.8 
Konno, Japan, 1993 32 1990-1991 4,110 Adult 29     0.68 3.13  
Galofre, Spain, 1994 170 1990-1992 103,098 15–85 57  10.9 73.4 45.6    
Vanderpump, UK, 199527 1975-1994 1,877 38-93 56 102µg/g-cr 60 350 243 1.3 9.3 5.8 
Bjoro, Norway, 200031 1995-1997	 94,009 >20 50     0.4 0.8 0.7 
Canaris, USA, 200095 1995 24,337 >18 56       0.4 
Hollowell, USA, 200224 1988-1994	 13,344 >12  145 µg/l      0.3 
Volzke, Germany, 2003171 1997-2001	 3,941 20-79 48 12µ g/dL      0.7 
Flynn, UK, 200496 1993-1997	 369,885  >0   88 498 297   3.0 
O’ Leary Australia 2006172 1981 2,115 16-89 50     0.37 0.65 0.54 
Teng†, China, 2006 (total) 108 1999 3761 (total) ≥18 69        
Teng†, China, 2006 (excess) 108 1999 1074 ≥18        2.0 
Teng†, China, 2006 (sufficient) 108 1999 1584 ≥18        0.9 
Sichieri, Brazil, 2007 (White) 98 2004-2005 1200 ≥35 100      1.6  
Sichieri, Brazil, 2007 (Mixed) 98 2004-2005         1.27  
Sichieri, Brazil, 2007 (Black) 98 2004-2005         0.59  
Leese, UK, 2007173 1994-2001 388,750 >0 52  101.0 457.0  1.0 5.5 3.0 
Kasagi, Japan, 2009100 2005-2006 1818 51.3+/-9.0 56     0.16 0.50 0.66 
Lucas, Spain, 2010174 2002 1,124 18-74 56 150 µg/l    0 0.5 0.2 
Sgarbi, Brazil, 201099 1999-2000 1110 >30 53     0.4 0.4 0.8 
Asvold, Norway, 201293 1995-2008 15,106 >20 67  113 317 249    
Marwaha, India, 2012178 2007-2010 4402 18-90 63       4.2 
Delshad, Iran, 2012 175 1999-2005 1,999 >20 61  21 28     
Unnikrishnan, India, 2013†109 2011 5376 18-100 54       10.95 
Sriphrapradang, Thailand, 2013176 2009 2545 ≥14        0.74 
	 	 	 	 	 	 	 	 	 	 	
		
IODINE DEFICIENT  
Laurberg, Denmark, 1999179 24 months 569,108 >0 51 60 µg/day 3.6 22.9 13.5    
Aghini-Lombardi, Italy, 199937 1995 992 >15 58 55 µg/l    0 0.3 0.2 
Knudsen, 1999, Denmark104 1993-1994 2,613 41-71 49 70 µg/l    0.2 0.5 0.3 
Knudsen, 2000, Denmark30 1997-1998 2,293 18-65 79 45 µg/l      0.2 
Knudsen, 2000, Denmark30 1997-1998 2,067 18-65 79 61 µg/l      0.6 
Hoogendoorn, 2006, 
Netherlands177  
2002-2003 5,167 >18 54     0.2 0.6 0.4 
Laurberg, 2006, Denmark36 1997-1998 310,124 18-65 50 68 µg/l 9.4 43.5 26.5    
Laurberg, 2006, Denmark36 1997-1998 225,707 18-65 53 53 µg/l 17.3 60.6 40.1    
Teng†, China, 2006 (deficient) 108 1999 1103 ≥18        0.3 
Du, China, 2014 (mildly deficient) 38  667 ≥18 71     0.15 0.90 1.05 
Data is for cases of overt hypothyroidism except where otherwise stated. Iodine status is based on reported status by authors; spaces are left blank where there is no data on 
incidence or prevalence or where the data is unclear from the report. †same study population, studied at 5 and 11 year intervals post iodizaton.†Data from 8 cities with a wide 
mix of iodine status from sufficient to deficient. Studies in specific population groups such as children, pregnant women, specificied co-morbid states, and unstable iodine 
nutrition are excluded 
 
	
	
	
	 	
	
		
Table 4: Longitudinal studies of iodine supplementation and frequency of hyperthyroidism and hypothyroidism 
Author, year, Country  Sample number 
Age, 
years  
Female, 
%  
Iodisation 
year  
Form of 
iodisation 
MUI, 
mcg/L 
Hypothyroidism  Hyperthyroidism  
Pre-
iodine 
Post-
iodine 
Pre-
iodine 
Post-
iodine 
Galofre, 1994, Spain180 103,098 15-85 57 1985 KI 60 mg/kg salt — — — 3.10/105 7.68/105 
Yang, 2002, China181           
 Panshan 1103 14-88 65 1996 USI 84 — — 28/105  81/105  
 Zhangwu 1584 14-95 69 1996 USI 243 — — 23/105 36/105 
 Huanghua 1074 14-79 66 1996 USI 651 — — 35/105 37/105 
Teng, 2006, China108           
 Panshan 884 19-80 68 1996 USI 88 — 1.2% — 5.3% 
 Zhangwu 1270 19-84 70 1996 USI 214 — 3.8% — 5.9% 
 Huanghua 1074 19-83 69 1996 USI 634 — 8.1% — 2.3% 
Golkowski, 2007, Poland182 1424 16+  66 1997 KI 30 mg/kg salt 112 — — 4.8% 6.5% 
Pedersen, 2007, Denmark136       — —   
 Aalborg 310124 >0 NS 1998 8-13 ppm  53 30/105 40/105 — — 
 Copenhagen 225707 >0 NS 1998 8-13 ppm  68 52/105 57/105 — — 
Heydarian, 2007, Iran183 1891 >20  1994 KI 40 mg/kg salt  328/105 25.2/105 88/105 63/105 
Cerqueira, 2011, Denmark184 5,300,000          
 Western region 2,920,000 >0 NS 1998 8-13 ppm  53 72/105 126/105   
 Eastern region 2,380,000 >0 NS 1998 8-13 ppm  68 87/105 163/105   
A-Lombardi, 2013, Italy185 2289 >1 64 2005 KI 30 mg/kg salt  55 2.8% 5.0% 2.1% 1.6% 
Tammaro, 2016, Italy142 7976  85 2005     2.5% 2.1% 
Hong, 2017, Australia140 389910 45+20 59 2001 Iodised bread 75 — 60% fall* — 62% fall* 
Prevalence figures are in % and incidence rates are in cases/105,  Figures represent overt and subclinical thyroid dysfunction. Age is in range or mean + standard 
deviation. KI, potassium iodide, USI, universal salt iodisation, ppm, parts per million, NS, not stated, MUI, median urinary iodine concentration at onset of programme. 
*fall in the incidence of overt thyroid dysfunction from 1995-2013. 
	 
Figure 1 Causes of Hypothyroidism and Hyperthyroidism 
 
 
 
 
 
 
 
 
	
Hypothyroidism 
Primary 
• Chronic auto-immune (Hashimoto 
thyroiditis) 
• Iodine status – severe iodine 
deficiency or mild to severe iodine 
excess 
• Iatrogenic – radioiodine or surgery 
(usually to treat hyperthyroidism, 
goitre or thyroid cancer) 
• Genetic (including variations causing 
congential hypothyroidism) 
• Pharmacological including 
amiodarone, lithium, monoclonal 
antibodies, anti-epileptic (Na 
Valproate), tyrosine kinase inhibitors), 
immune checkpoint inhibitors 
• Transient thyroidits post-partum, 
viral (De Quervain's syndrome),  
• Thyroid infiltration – infectious, 
malignant (primary thyroid or 
metatstatic) other autoimmune 
condtions such as sarcoidosis 
 
Secondary (central) 
• Hypothalmic failure/dysfunction 
• Pituitary (macroadenoma/ 
apoplexy) 
• Resistance to TSH or TRH 
• Pharmacological (e.g.dopamine, 
somatostatins)  
 
Extra-thyroidal 
• Consumptive hypothyroidism 
• Tissue specific secondary to genetic 
mutations (e.g. THRα, THRβ and 
MCT8) 
	
Hyperthyroidism 
Primary 
• Increased stimulation - secondary to 
TSH receptor antibodies (Graves’ 
disease), excess HCG secretion 
(hyperemesis gravidarum and 
trophoblastic tumours such as 
choriocarcinoma or hydatidiform 
mole)  
• Autonomous thyroid function  -(toxic 
multinodular goitre, solitary toxic 
nodule, familial non-auto immune 
hyperthyroidism 
• Excess release of stored thyroid 
hormone  - autoimmune (silent or 
postpartum thyroiditis) infective (viral 
- De Quervain thyroiditis, bacterial or 
fungal), pharmacological (amiodarone 
interferon α), radiation 
• Exposure to excess iodine known as 
the Jod Basedow effect (from excess 
iodine intake including radiographic 
contrast) 
 
Secondary (central) 
• Inappropriate TSH secretion (TSH 
secreting pituitary adenoma, pituitary 
resistance to thyroid hormone) 
 
Extra-thyroidal  
• Excess intake of thyroid hormone 
(iatrogenic or factictious)  
• Ectopic thyroid hormone secretion 
(Struma ovarii; functional thyroid 
cancer metastases) 
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